Cognitive Decline Reduced by 27%: New Alzheimer’s Drug Passes Phase III Clinical Trials
Lecanemab reaches primary clinical endpoint and all secondary clinical endpoints in the large-scale confirmatory Phase III clinical trial CLARITY.
Launched Amid Controversy, New ALS Drug Approved by the FDA
More than 200,000 patients worldwide are urgently awaiting the emergence of new drugs.
Sixty Years Later, the First Drug with a New Mechanism is Approved, Potentially Changing the Paradigm of Antidepressant Treatment
Axsome is expected to be the first to launch Auvelity in the United States in the fourth quarter of this year.
The Enigma of Alzheimer’s Drug Development: Why is the Failure Rate as High as 99.6%?
Why has Alzheimer's disease become the 'graveyard of new drug development'?
How Does the Brain Make You ‘Sick’?
让你发烧的神经元会成为新药靶点吗？
我们为何仍未攻克阿尔茨海默病？
在最难攻克的大脑疾病面前，我们是否止步不前？